Share-based Payment Arrangement, Expense of Mersana Therapeutics, Inc. from 31 Dec 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Mersana Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2015 to 30 Sep 2025.
  • Mersana Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,154,000, a 71% decline year-over-year.
  • Mersana Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $9,264,000, a 46% decline year-over-year.
  • Mersana Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $16,458,000, a 22% decline from 2023.
  • Mersana Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $21,136,000, a 1.8% decline from 2022.
  • Mersana Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $21,522,000, a 17% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Mersana Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $9,264,000 $1,154,000 -$2,873,000 -71% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $12,137,000 $1,989,000 -$2,436,000 -55% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $14,573,000 $2,775,000 -$1,885,000 -40% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $16,458,000 $3,346,000 -$739,000 -18% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
Q3 2024 $17,197,000 $4,027,000 +$26,000 +0.65% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $17,171,000 $4,425,000 -$2,218,000 -33% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $19,389,000 $4,660,000 -$1,747,000 -27% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $21,136,000 $4,085,000 -$1,229,000 -23% 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $22,365,000 $4,001,000 -$1,374,000 -26% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $23,739,000 $6,643,000 +$1,295,000 +24% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $22,444,000 $6,407,000 +$922,000 +17% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $21,522,000 $5,314,000 +$454,000 +9.3% 01 Oct 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
Q3 2022 $21,068,000 $5,375,000 +$447,000 +9.1% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $20,621,000 $5,348,000 +$766,000 +17% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $19,855,000 $5,485,000 +$1,446,000 +36% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $18,409,000 $4,860,000 +$2,871,000 +144% 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
Q3 2021 $15,538,000 $4,928,000 +$3,010,000 +157% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $12,528,000 $4,582,000 +$2,926,000 +177% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $9,602,000 $4,039,000 +$2,430,000 +151% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $7,172,000 $1,989,000 +$727,000 +58% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $6,445,000 $1,918,000 +$633,000 +49% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $5,812,000 $1,656,000 +$495,000 +43% 01 Apr 2020 30 Jun 2020 10-Q 06 Aug 2021 2021 Q2
Q1 2020 $5,317,000 $1,609,000 +$445,000 +38% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $4,872,000 $1,262,000 +$132,000 +12% 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $4,740,000 $1,285,000 +$232,000 +22% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $4,508,000 $1,161,000 +$205,000 +21% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020 2020 Q2
Q1 2019 $4,303,000 $1,164,000 +$419,000 +56% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020 2020 Q1
Q4 2018 $3,884,000 $1,130,000 +$697,000 +161% 01 Oct 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
Q3 2018 $3,187,000 $1,053,000 +$680,000 +182% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $2,507,000 $956,000 +$604,000 +172% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $1,903,000 $745,000 +$481,000 +182% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $1,422,000 $433,000 01 Oct 2017 31 Dec 2017 10-K 28 Feb 2020 2019 FY
Q3 2017 $373,000 +$177,000 +90% 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018 2018 Q3
Q2 2017 $352,000 +$221,000 +169% 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018 2018 Q2
Q1 2017 $264,000 01 Jan 2017 31 Mar 2017 10-Q 15 May 2018 2018 Q1
Q3 2016 $196,000 01 Jul 2016 30 Sep 2016 10-Q 13 Nov 2017 2017 Q3
Q2 2016 $131,000 01 Apr 2016 30 Jun 2016 10-Q 11 Aug 2017 2017 Q2

Mersana Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $16,458,000 -$4,678,000 -22% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
2023 $21,136,000 -$386,000 -1.8% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
2022 $21,522,000 +$3,113,000 +17% 01 Jan 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
2021 $18,409,000 +$11,237,000 +157% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
2020 $7,172,000 +$2,300,000 +47% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $4,872,000 +$988,000 +25% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $3,884,000 +$2,462,000 +173% 01 Jan 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
2017 $1,422,000 +$758,000 +114% 01 Jan 2017 31 Dec 2017 10-K 28 Feb 2020 2019 FY
2016 $664,000 +$315,000 +90% 01 Jan 2016 31 Dec 2016 10-K 08 Mar 2019 2018 FY
2015 $349,000 01 Jan 2015 31 Dec 2015 10-K 28 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.